(Image from Lyra Therapeutics)
Lyra Therapeutics (NSDQ:LYRA) announced today that it entered into a strategic partnership with LianBio for its LYR-210 treatment for chronic rhinosinusitis.
Watertown, Mass.-based Lyra, which develops the LYR-210 therapeutic to be locally delivered by its proprietary XTreo platform, could receive up to $135 million in total payments through the strategic partnership and exclusive license agreement for development and commercialization in Asia with LianBio.
Get the full story at our sister site, Drug Delivery Business News.